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Background: Claudins are key integral proteins of the tight junction. Although they play an essential role in
controlling paracellular diffusion in epithelia, increasing evidence supports a role for these proteins in non-barrier
forming activities. To elucidate a potential function for claudins outside of their traditional role in tight junctions,
subcellular localization of claudin-4 was determined in normal mammary epithelial cells as well as breast and
ovarian cancer cell lines and the effects of a claudin mimic peptide on cell motility were determined.
Results: Immunofluorescence revealed that claudin-4 was localized along cellular projections. Using a fluorescent
peptide that mimics a conserved sequence in the second extracellular loop of a set of claudin subtypes, that
includes claudin-4, exposure of this loop to the extracellular environment was confirmed in non-polarized cells. This
peptide inhibited cell motility when normal mammary epithelial cells as well as breast and ovarian tumor cells were
subjected to a wound healing assay. Knockdown of claudin-4 also inhibited cell motility and the mimic peptide had
no effect on motility in the claudin-4 knockdown cells. This effect on motility was seen when cells were grown on
collagen, but not when cells were grown on non-physiological cell adhesive or fibronectin.
Conclusion: The second extracellular loop of claudins is able to interact with the extracellular environment to
promote normal and tumor cell motility when it is not associated with tight junction structures.
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Claudins are important transmembrane proteins in tight
junctions. They are best known for their homo- and
heterotypic interactions between adjacent epithelial cells
that control the tissue-specific paracellular permeability
properties of epithelia. Although the structure and
functions of the 27 different subtypes [1] of claudin are
not fully understood, the tight junction barrier properties
of claudins have been well characterized. Immunohisto-
chemistry and immunofluorescence analysis of claudin
localization in normal tissue shows that some claudin
subtypes are not restricted to the tight junction.
Extra-junctional claudins have been traditionally attributed
to storage and mobilization of claudins to and from the
tight junction. For example, Shen [2] and colleagues have
elegantly demonstrated through FRAP (recovery of fluores-
cence after photobleaching) analysis that the tight junction* Correspondence: Heidi.Wilson@ucdenver.edu
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reproduction in any medium, provided the oris constantly remodeling. However, Blackman et al. [3] have
shown that claudin-7 is present in mammary epithelial
cells at fair levels at all stages of development but never
localizes to the tight junction. Instead, it is found in
cytosolic vesicle-like structures near the basolateral
membrane in these cells as well as cells in the pulmonary
bronchus and the renal cortex. Basolateral localization of
claudin-1, –3, –4, –7 and –8 has also been identified in
intestinal epithelium by Chiba et al. [4] and Ding et al. [5]
Ding and colleagues found that intestinal function was
seriously compromised in claudin-7 knockout mice. This
observation suggests that non-junctional stores of claudin
may potentially be involved in activities of normal
epithelia in addition to replenishing tight junction claudin.
A potential function for claudins not localized within
tight junction structures can also be supported by the
observation that during tumor progression, where
disruption and loss of tight junction structures is a
hallmark characteristic, certain claudin subtypes are
distinctly expressed. Claudins −3, –4 and −7 are often
present in breast [6-8], ovarian [9-11], and endometrialtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Using serial analysis of gene expression (SAGE), Kominsky
and coworkers have shown both that claudin-4 is
expressed in the majority of breast tumors tested and that
expression is increased 2–3 fold compared to normal
breast tissue [14]. Furthermore, claudin-3 and −4 are not
normally expressed in ovarian surface epithelium, but are
highly expressed in 70% of ovarian tumors [10]. Although
over expression of claudins is well documented in
epithelial-derived cancer cells, the role of claudins in
tumor promotion has received little attention.
Increasing evidence supports a role for claudin proteins
in cell motility. Agarwal and colleagues observed an
increase in cell motility when normal human ovarian
surface epithelial cells (HOSE) were transfected with
claudin-3 or claudin-4 compared to non-transfected HOSE
cells, which do not express these claudins [15]. A similar
phenomenon was observed in gastric adenocarcinoma cells,
where forced over expression of claudin-6, –7, and −9
increased the motility of these cells compared to non-
transfected gastric adenocarcinoma cells [16]. Alternatively,
the loss of claudin-11 (also known as oligodendrocyte-
specific protein) was shown to impair migration of primary
oligodendrocytes [17] and loss of claudin-5 in the breast
cancer cell line MDA-MB-231 cells inhibited cell motility
[18]. The mechanisms by which claudins influence cell
motility are not well understood. However, a few studies
have found claudins within protein complexes that contain
important motility molecules such as CD44v6/EpCAM/
CO-092 in colorectal cancer cells [19] and N-WASP
/ROCK in metastatic breast cancer cells [18]. Miyamori
and colleagues [20] have also shown that claudin-1, –2, –3,
and −5 have the potential to interact with the MT1-MMP
metalloproteinase and that this interaction can enhance the
processing and activation of MMP-2, an important
metalloproteinase involved in promoting cell motility via
degradation of the extracellular matrix.
To further clarify how claudins may function as both a
tight junction protein as well as a potential motility
molecule, we have focused our attention on the proposed
structure of claudin. Claudins span the membrane four
times, with cytosolic N- and C-terminal domains and two
extracellular loops. This structure gives them the potential
to mediate interactions between the intracellular and
extracellular environment. The cytosolic C-terminal
domain of claudins contains a PDZ-binding domain
that is known to bind the cytoplasmic plaque proteins
ZO-1, ZO-2, and ZO-3 [21] thus linking the tight junction
to the cytoskeleton. Signaling molecules, such as MAGI,
MUPP1 and Par-3, are also known to contain PDZ
domains and although the PDZ binding protein partners
of claudin have received little study, there is a strong
potential for claudins to play an important role in cell
signaling mechanisms. The extracellular loops of claudinare also key domains that are known to contribute to
claudin function. These loops are known to interact with
specific claudin subtypes on opposing epithelial cells as
well as with claudin subtypes within the same plasma
membrane [22-24]. Claudin extracellular loops have also
been shown to interact with occludin [25], another integral
protein of the tight junction. These claudin-claudin and
claudin-occludin interactions are important for forming
the protein strands of the tight junction. During
pathological conditions, claudin extracellular loops are
targeted by and interact with pathogens such as hepatitis
C virus [26] and Clostridium perfringens enterotoxin [27].
The question remains whether or not the extracellular
loops of claudins may normally interact with components
of the extracellular milieu such as the extracellular matrix
proteins, particularly since claudins have been found
localized at or near basolateral membranes of normal
epithelium.
In this study we investigated the potential function of
claudin-4 in promoting cell motility, specifically testing the
hypothesis that claudin-4 directs cell movement through
extracellular loop interactions. With immunofluorescence,
we found claudin-4 localized along cellular projections of
both normal and tumor cells. Using a small peptide that
mimics a conserved sequence in the second extracellular
loop of subset of claudin subtypes, including claudin-4
[28], we were able to determine that the second extracellu-
lar loop of non-tight junctional claudins is exposed to the
extracellular environment in non-polarized cells and that
interruption of this loop’s normal interactions inhibits cell
motility. The inhibition of cell motility is strongest
with cells plated on collagen, suggesting a potential
interaction of claudin with extracellular molecules to
promote cell movement.
Results
Claudins are found in cellular projections
We first used immunostaining to localize claudin-4 in both
normal mammary epithelial cells and breast tumor cells.
Previously, we had demonstrated that localization of
claudin-3 and claudin-4 is restricted to the tight junction
in confluent monolayers of normal mouse mammary
epithelium in culture, using the established cell line EpH4
[28] as well as primary mammary epithelium isolated from
wild type FVB mice [29]. However, when we examined
claudin-4 localization in these primary mammary
epithelial cultures before they reached confluence,
we found it within distinct puncta along thread-like
projections between adjacent cells (Figure 1A).
Claudin-4 co-localized with the tight junction protein
ZO-1 at the cell boarders as well as in a few of the cell
projections. This zipper-like appearance is similar to
what is seen in early or primordial junction formation. To







Figure 1 Claudin-4 localization in normal and tumor cells. Representative confocal microscopy images of fixed subconfluent primary
mammary epithelial cells (A) and breast cancer 21PT cells (B) treated with antibodies directed to claudin-4 (A: red, B: green) and/or ZO-1 (A:
green) and stained with DAPI (A&B: blue) and/or phalloidin (B: red). Claudin-4 localizes within distinct puncta in the cytosol near the nucleus
as well as along cellular projections. Arrows point to claudin-4 puncta in cellular projections in both normal and tumor cells. Yellow color of
the merged image (A) indicates overlay of the red claudin and the green ZO-1 immunofluorescence.
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junction structures, we examined localization of claudin-4
in breast cancer cells. We chose several breast cancer cell
lines to investigate. A breast cancer progression series,
which includes a cell line isolated from a primary breast
tumor (21PT) and a line isolated from a metastatic lesion
(21MT) from the same patient, was first examined.
Claudin-4 appeared in distinct cytosolic puncta or vesicle-
like structures, often found on one side of the cell or along
cellular projections in non-confluent cultured cells. These
puncta were common at sites where the projection
touched another cell and at the end of the projections
(Figure 1B). Unexpectedly, a similar pattern of claudin-4
localization was seen in both the primary and metastatic
cells lines (data not shown).Cell projections, such as lamelipodia and filopodia, play
an important role in cell motility in both normal and tumor
cells. Finding claudins in the thread-like projections be-
tween normal mammary epithelial cells as well as at the
end of filopodia in tumor cells suggested that claudins
could potentially be playing a role in directing cell motility.
Although claudin-4 puncta are found within and at the end
of cellular projections, immunofluorescence staining of
fixed cells did not reveal a strong presence of claudin-4 at
the plasma membrane. To determine whether claudin-4
can reach the cell surface, at least temporarily, we
treated cells with a fluorescently labeled DFYNP mimic
peptide (Figure 2A). We have previously characterized the
specificity of this small mimic peptide, showing that the

























Figure 2 Claudin is exposed to the extracellular environment in non-polarized cells. (A) Model of the proposed structure of claudin proteins.
The FITC-linked DFYNP peptide mimics the DFYNP sequence in the second extracellular loop of the claudin subtypes that express this conserved
sequence. 21MT1 (B) and T47D (C) cells were treated with 400µM FITC-DFYNP for 1 hour at 4°C, washed 3 times with ice-cold PBS and immediately
imaged live with a confocal microscope to prevent cellular uptake. Representative images show FITC-DFYNP peptide (green) bound at the surface
of 21MT1 and T47D cells when treated and washed at 4°C. Cells were stained with DAPI (B&C: blue, with leakage of DAPI stain into cytosol of 21MT1
cells) and/or phalloidin (B: red). (D) FITC-peptide treated T47D cells, at 4°C, were then fixed and treated with a fluorescent antibody directed to
claudin-4 (green) and stained with DAPI (blue) and phalloidin (red). Fluorescence was imaged with a confocal microscope.
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surface at sites of tight junctions [28]. We have also shown
that the peptide does not bind to the cell surface of cells
that do not express claudins or when glycine is substituted
for the any of the last four amino acids of the peptide [28].
Because we have shown that the DFYNP peptide can
target claudin-4 we treated tumor cells with the fluorescent
mimic peptide at 4°C for one hour before washing the cells
with ice cold PBS and subjecting them to immediate
imaging. At 4°C, endocytosis is inhibited. Therefore, ifclaudins are in the membrane at the time of chilling and the
extracellular loop is exposed to the extracellular environ-
ment, the fluorescent peptide should bind and stay at the
membrane to be visualized with the confocal microscope.
Fluorescent images show that the peptide does indeed bind
to the membranes of both 21MT1 and T47 breast tumor
cells (Figure 2B). Because T47D breast cancer cells are
known to express high levels of claudin-4, we expected more
peptide to be bound to their surface (Figure 2C) compared to
the 21MT1 cells. As shown in Figure 2C, our expectations
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main attached to cells with fixation and the extensive wash-
ings involved in immunofluorescence, we did see a strong
fluorescent signal for claudin-4 at the plasma membrane of
T47D cells (Figure 2D). These observations suggest that
claudins are able to reach the surface of both normal and
tumor cells even when they are not associated with trad-
itional tight junction structures. It is important to note that
these images are projected images from z-stacks. Due to the
thickness of the z-stack for the 21MT1 cells, some apparent
internal peptide is, in fact, peptide bound to the upper sur-
face of the cell.
The second extracellular loop of claudin-4 plays a role
in motility
To test whether claudins, particularly claudin-4, could play





















Figure 3 Disturbing claudin extracellular loop interactions with DFYN
of DAPI (nuclei) staining in 16N, T47D, 21MT1, cells, grown on 100 µg/ml col
(T47D, 21MT1) hours post scratch treatment with control medium (top pane
mean distance across the gap at 4 (16N, EpH4) or 24 (T47D, 21MT1, MCF-7, O
each cell line for each condition. Mean ± s.e.m., n=3 wells for each treatmenextracellular interactions, we treated normal and tumor
cells with the mimic peptide and examined changes in cell
motility. We examined motility of normal mammary epi-
thelial cells, using both mouse EpH4 and human 16 N cell
lines. We also examined motility in human cancer cells
lines that lack normal tight junctional organization as deter-
mined by loss of ZO-1 expression (data not shown) and are
either known to overexpress claudin-4 (T47D, MCF-7,
OVCAR3) or known to be particularly aggressive tumor
cells (21MT1). Monolayers, grown on collagen type I plus
Cell-Tak-coated glass chamber slides, were wounded by
scratching with a pipette tip and the medium was replaced
with medium plus or minus 400 μM mimic peptide. We
have previously shown that this concentration of peptide
disrupts tight junction claudin without altering overall
epithelial integrity [28]. Because normal cells show
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l of A) or medium with 400µM DFYNP peptide (bottom panel of A). The
VCAR3) hours post scratch was measured, using SlideBook software, for
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Figure 4 Peptide with glycine substitution does not inhibit cell
motility. T47D cells were grown to confluence on 100 µg/ml
collagen type I + 3.5 µg/cm2 Cell-Tak-coated slides. After the cells
were scratched medium was replaced with fresh medium minus
peptide (white bar), medium plus 400 µM DFYNP peptide (“+P”,
black bar), or medium plus 400 µM DFgNP peptide (“+gP”, gray
bar). Mean ± s.e.m., n=4 wells for each treatment (20 measurements
taken for each well) *p < 0.05 vs. non-treated.
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Figure 5 Claudin-4 knockdown inhibits cell motility. Representative
confocal microscopy images (A) of fixed T47D cells and T47D cells
with claudin-4 knocked down by shRNA technology [“T47D(-)cld4”]
analyzed by immunofluorescence for claudin-4. Western blot analysis
(B) confirmed a significant decrease in claudin-4 protein expression
in T47D(-)cld4 cells compared to T47D cells. A scratch assay was
performed on monolayers of both T47D and T47D(-)cld4 in the
absence or presence (+P) of 400 µM DFYNP peptide for 24 hours
and the distance across the gap at 24 hours was measured (C).
Mean ± s.e.m., n=4 wells for each treatment (20 measurements
taken for each well) *p < 0.05 vs. non-peptide treated.
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EpH4 and 16 N cells or 24 hours post scratch for T47D,
MCF-7, 21MT1, and OVCAR3 cells. In both normal and
cancer cell lines, there was a significant decrease in the
rate at which cells moved into the wound when cells were
treated with the mimic peptide compared to control cells
as shown both in the images in Figure 3A and in the
size of the gap quantitated in Figure 3B. These results
provide evidence that cell motility is inhibited when
claudin extracellular interactions are disturbed in both
normal and tumor cell lines, despite the differences in in-
herent motility.
To test the specificity of the peptide in this effect,
we treated wounded T47D cells with a mimic peptide
synthesized with glycine substituted for tyrosine (designated
“+gP”). The size of the gap remaining after 24 hours was
not significantly different between control cells and cells
treated with the glycine-substituted peptide (Figure 4). As
in Figure 3B, the un-substituted peptide significantly
increased the size of the gap.
To confirm that claudin-4 is indeed the target of the
peptide that is influencing cell motility, we knocked-down
claudin-4 in T47D cells using shRNA technology. Im-
munofluorescent analysis for claudin-4 in the shRNA
treated cells (designated “T47D(−)cld4”) showed very little
claudin-4 protein; only isolated cell patches of cells
displayed low-levels of claudin-4 (Figure 5A). Western
blot analysis (Figure 5B) confirmed a significant
decrease in claudin-4 expression in the T47D(−)cld4
cells compared to T47D cells. Scratch assays were then
performed on T47D versus T47D(−)cld4 in the presence
or absence of 400 μM mimic peptide. In the absence ofthe mimic peptide, T47D(−)cld4 cells moved more
slowly to heal the wound than T47D cells (Figure 5C,
open bars), confirming that loss of claudin-4 inhibits
cell motility. Treatment of T47D(−)cld4 cells with the
mimic peptide had no effect on cell motility, confirming
that claudin-4 is the target of the mimic peptide that is
influencing cell motility.
Extracellular matrix proteins important for claudin-
facilitated cell motility
To determine whether claudins interact with or require


























Figure 6 Disruption of wound healing by the peptide is seen only in the presence of collagen. Representative confocal microscopy images
of DAPI (nuclei) staining of normal 16N human mammary epithelial cells and T47D and 21MT1 breast tumor cells, grown on 3.5 µg/cm2 Cell-Tak-
coated slides (A) at 4-24 hours post scratch treatment with control medium (top panel of A) or media with the 400 µM DFYNP claudin mimic
peptide (bottom panel of A). The size of the gap at 4 (normal cells: 16N, EpH4) or 24 (tumor cells: T47D, 21MT1, MCF-7, OVCAR3) hours post scratch
was measured, using SlideBook software, for each cell line for each condition. Mean ± s.e.m., n=3 wells for each treatment (20 measurements taken
for each well) *p < 0.05 vs. non-treated.
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slides coated with Cell-Tak, a non-physiological matrix
derived from mollusk polyphenolic proteins. Interestingly,
when grown on Cell-Tak, the EPH4 cells migrated much
more quickly into the scratch and the 16 N cells moved at
about the same speed (compare the length of the corre-
sponding open bars in Figures 3 and 6). However, the
mimic peptide did not inhibit this movement (Figure 6A
and B), with a similar sized gap for treated and untreated
cells. The tumor cells moved much more slowly on
Cell-Tak compared to collagen (again compare the
lengths of the open bars in Figures 3 and 6), with only
21MT1 and OVCAR3 cells showing a small, but significant,
difference in gap size between treated and untreated cells.
These data suggest that although normal and tumor cells
behave differently on different extracellular matrices, themotility of both cell types involves an extracellular inter-
action of claudin that appears to require collagen matrix.
To further investigate the potential requirement for
specific extracellular matrices in claudin-facilitated motil-
ity, we examined movement of select cells on fibronectin.
Normal human mammary epithelial cells (16 N), breast
tumor cells (T47D) and ovarian tumor cells (OVCAR3)
were all grown on fibronectin-coated glass slides. Conflu-
ent monolayers were scratched and the size of the gap
remaining at 4 hours (16 N) or 24 hours (T47D,
OVCAR3) was measured. T47D cells moved more rapidly
on fibronectin than on Cell-Tak. However, OVCAR3 and
16 N cells moved at about the same speed judging from
the size of the gap on the two matrices. However, motility
of all three cell lines was unchanged in the presence or

























Figure 8 Proliferation does not influence the wound healing
response. Representative confocal microscopy images of nuclei
(DAPI, red) and Ki67 (yellow) in T47D cells, grown on 100 µg/ml
collagen type I + 3.5 µg/cm2 Cell-Tak, 24 hours post scratch in
absence or presence of the mimic peptide (A). The size of the gap
remaining at 24 hours post scratch treatment was measured for T47D
cells plated on Cell-Tak (ctT47D) or collagen (cT47D). After the scratch
the media was replaced with either normal media plus (+P) or minus
DFYNP peptide in the absence or presence (+m) of mitomycin-C. The
inhibition of wound healing with the DFYNP peptide was similar in
cells treated with mitomycin-C compared to untreated cells. Mean ±
s.e.m., n=3 wells for each treatment (20 measurements taken for each
well), *p < 0.05 vs. non-treated, NS=not significant.
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Figure 7 Wound healing response to peptide is specific for
collagen. Normal human mammary epithelial (16N) as well as breast
(T47D) and ovarian (OVCAR3) tumor cell monolayers, grown on 30
µg/ml fibronectin-coated glass chamber slides, were scratched and
the size of the gap remaining at 4 (16N) or 24 (T47D, OVCAR3) hours
was measured using SlideBook software. The size of the gap was
compared between non-treated cells (white bars) and cells treated
with 400 µM mimic peptide. Mean ± s.e.m., n=4 wells for each
treatment (20 measurements taken for each well) *p < 0.05 vs. non-
treated.
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role in the inhibition of motility
To confirm that inhibition of proliferation is not playing a
role in the reduced wound closure response induced by
the mimic peptide, T47D cells were treated with an
antibody directed to Ki67, a marker of cell proliferation. A
similar number of Ki67 positive cells was seen in treated
cells compared to untreated cells (Figure 8A), suggesting a
similar rate of proliferation in both conditions. In a separ-
ate set of experiments, cells were treated with mitomycin-
C for two hours prior to wounding as well as during
treatment with the mimic peptide to inhibit cell prolifera-
tion. In the presence of mitomycin-C, the effects of the
mimic peptide were similar to those seen in the absence
of mitomycin-C (Figure 8B). When cells were grown on
Cell-Tak, only a small effect of the peptide was seen, con-
sistent with the results in Figure 6B, whereas a highly sig-
nificant effect of peptide was seen on the collagen matrix
as before. Importantly mitomycin-C had no significant
effect in the size of the gap in peptide treated cells on ei-
ther matrix. These results indicate that cell proliferation is
not an important part of the response to wounding under
any conditions, since mitomycin C treatment did not alter
the size of the gap under any of the observed conditions.
To determine whether increased apoptosis could be
playing a role in the reduced rate of wound repair seen with
the peptide, caspase-3 activation was examined in both un-
treated and DFYNP treated cells. Immunofluorescence of
active caspase-3 revealed a low and insignificantly different
level of caspase-3 activation in untreated (2.34 ± 0.43% ofthe total cell population stained positive for caspase-3
activation) and treated (3.27 ± 0.38% of the cell population
stained positive for caspase-3 activation) T47D cells
grown on collagen plus Cell-Tak. Importantly, caspase-3
activation was seen throughout the monolayer and was
not restricted to the edges of the scratch (data not shown);
further indicating that increased apoptosis is not playing a
role in the peptide-induced change in cell motility.
Discussion
In this study we have shown that claudin-4 can be found
in puncta along cellular projections of non-confluent
normal mammary epithelial cells as well as breast tumor
cells. Claudin-4 can reach the surface of these cells,
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extracellular environment in the absence of established
tight junction structures. Both disturbing normal second
extracellular loop interactions with a mimic peptide and
knock-down of claudin-4 expression inhibited wound
healing, providing strong evidence for a role for claudin-4
in cell motility when cells are grown on extracellular
matrices containing collagen.
These results are consistent with previous reports in
which claudin expression was associated with changes in
cell motility [15-19]. Agarwal et al. [15] showed that
forced expression of claudin-4 in cells that don’t
normally express claudin-4 increased cell motility. We
have shown that claudin-4 can also promote motility in
cells that normally express claudin-4 and that both
normal cells and different types of tumor cells all exhibit
the same phenomenon. It is, therefore, possible that
claudin-4-faciltated motility may represent a fairly
common mechanism used by cells of epithelial origin to
direct cell movement.
The motility slowing effect of the function-blocking
peptide, DFPNY, provides the first direct evidence that
claudin-4 is promoting cell motility through interactions
of its extracellular loop. The finding that the effect was
only seen, in our experiments, when collagen was
included in the extracellular matrix provides strong
evidence to support the notion that the interaction
includes matrix proteins. The nature of this interaction
will require more detailed investigation. It is possible
that claudin-4 interacts directly with collagen to pro-
mote cell motility or it may interact with other proteins
that are known to interact with collagen. Ding et al. [5]
showed that claudin-1 and claudin-7 form a complex
with integrin α2 at the basolateral membrane of normal
mouse intestine. Integrins are well known receptors for
extracellular matrix proteins, with integrin α2 a known
receptor for collagen. Additionally, claudin-7 has been
shown to complex with a CD44 in colorectal cancer cells
[19,30]. CD44 is a surface glycoprotein that has been
shown to bind to hyaluronan, as well as collagen, to
promote tumor cell motility [31]. Although a direct
interaction of claudin-4 with CD44 has yet to be
confirmed, CD44 expression has been found to be
associated with claudin-4 expression in particularly
aggressive ovarian tumor cells [32]. Claudin expression
has also been associated with matrix metalloproteinases
(MMPs). MMPs are secreted zinc-endopeptidases that
are known to degrade extracellular matrix and enhance
cell motility, particularly in collective cell migration [33].
An investigation of HOSE cells transfected with claudin-3
or −4 showed an increase in MMP-2 activity in cells
expressing the claudins versus normal non-expressing
HOSE cells [15]. Takehara et al. [34] also observed
increased MMP-2 and MMP-9 activity in Caco-2 cellsover expressing claudin-3 or −4 compared to mock
transfected Caco-2 cells. These observations, along with a
report by Miyamori et al. [20] that claudins have the
potential to interact with MT1-MMP to activate MMP-2,
suggest that claudins may increase MMP activity to digest
extracellular matrix and promote cell motility. All these
observations are consistent with a critical role of collagen
for claudin-enhanced motility.
The focus of this study has been on claudin-4. It is
possible that other claudin subtypes may be involved in
cell motility, especially those subtypes with the DFYNP
sequence. Claudin-3 has been shown to increase cell
motility when expressed in ovarian surface epithelial cells
that don’t normally express claudin-3 [15]. Interestingly,
claudin-5 and claudin-11 have been implicated in
promoting motility, but do not have the DFYNP
sequence in the second extracellular loop. It is possible
that these claudin subtypes use a different mechanism to
promote motility and may even take advantage of other
key domains of claudin structure such as the cytosolic
PDZ-binding domain. It is even possible that the extracel-
lular loop of claudin-4 may promote motility through
initiation of intracellular signaling pathways.
Although it is still unclear how claudins may promote
cell motility, it is becoming clear that claudins are
indeed playing an important role in promoting cell
movement during wound healing. Why claudins play a
role in cell motility is another unresolved question.
However, our hypothesis is that non-junctional claudins
have lost their normal connections to a partner claudin
through the lack of a neighboring cell. They may,
therefore, be sampling the extracellular environment and
directing cell movement to find a partner. This process
would be critical in wound repair when epithelial cells
are moving in to quickly cover defenseless tissue and
re-establish the protective barrier that epithelial cells
provide. It is interesting to note that an examination
of gene expression during normal mammary gland
development showed a sharp increase in claudin-3
and −4 expression during early days of involution
[35,36], a time of significant tissue remodeling. Could
these claudins have a designated role in cell motility
during this window when both dissolution and healing of
the mammary epithelium is taking place? Is it possible
that this process becomes significantly disrupted in tumor
cells? Perhaps these non-junctional claudins in tumor cells
are unable to interact with neighboring claudins, leading
them to continue to migrate in undesired directions.
Clearly, many questions remain about how claudins
promote cell motility, especially since they are traditionally
thought of as stabilizing proteins. However, the relevance
to normal wound healing responses as well as tumor pro-
gression opens an exciting new area in the understanding
of claudin function.
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In summary, we have shown that claudin-4 promotes
both normal and tumor cell motility through key
extracellular loop interactions. Claudin-4 can be found
in cellular projections, where it can cycle from the cyto-
sol to the membrane and expose the DFYNP sequence
of the second extracellular loop to the extracellular
environment. In the absence of a neighboring cell, the
second extracellular loop then interacts either directly
or indirectly with collagen to direct cell movement.
Methods
Cell culture
Primary mammary epithelial cells were isolated from
the mammary glands of female FVB mice (Jackson
Laboratories, Bar Harbor, Maine, USA). The fourth
and fifth mammary glands were dissected from pregnancy
day 15 dams. The minced glands were placed in collage-
nase solution consisting of: Dulbecco’s Modified Eagle
Medium: Nutrient Mixture F-12 (DMEM/F12) media
(Mediatech, Manassas, VA), 2 mg/ml Collagenase A
(Roche Applied Science, Indianapolis, IN), and 50 μg/ml
Gentamycin (Mediatech), and incubated at 37°C with
shaking at 200 rpm for 2 hours. Cells were then spun at
1500 rpm for 10 minutes and the pellet was pulse washed
with PBS (with calcium and magnesium) 5 to 10 times at
1500 rpm for 2 seconds. The pellet, which contains
mammary epithelial organoids, was then resuspended in
growth media containing: DMEM/F12 media, 1X ITS
(10X stock, Sigma, St. Louis, MO), 100 μg/ml EGF (BD
Biosciences, San Diego, CA), 5% FBS (Mediatech),
50 μg/ml gentamycin (Mediatech), 1% penicillin/
streptomycin (Mediatech), and 2.5 μg/ml FUNGIZONE
(Gibco, Grand Island, NY); and plated on 8-well chamber
slides coated with Collagen I (Sigma, St. Louis, MO).
EpH4 cells were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 5% heat-inactivated
fetal bovine serum (FBS), 1% penicillin/streptomycin, and
10 mM Hepes (Mediatech). 16 N, 21PT and 21MT1
(kindly provided by Heide L. Ford) cells were grown in
DMEM supplemented with 10% heat-inactivated FBS, 1%
penicillin/streptomycin, 1% non-essential amino acids
(Mediatech), 1 mM sodium pyruvate (Mediatech),
2 mM L-glutamine (Mediatech), 10 mM Hepes, 1 μg/ml
insulin (Sigma), 1 μg/ml hydrocortisone (Sigma), and
12.5 ng/ml EGF. T47D cells were grown in RPMI
(Mediatech) media supplemented with 10% FBS, and
6 ng/ml insulin. MCF7 cells were grown in Minimum
Essential Media (MEM, Mediatech) supplemented with
10% heat-inactivated FBS, 1% penicillin/streptomycin, 1%
non-essential amino acids (Mediatech), 1 mM sodium
pyruvate (Mediatech), 2 mM L-glutamine (Mediatech),
and 10 μg/ml insulin. OVCAR3 cells (kindly provided
by Monique A. Spillman) were grown in DMEMsupplemented with 10% FBS. Cells were trypsinized
(0.25% Trypsin, EDTA, Mediatech) and plated every 3–4 -
days. Cells were plated, 2×104 cells/well (21PT, 21MT1,
T47D, MCF7, OVCAR3) or 1×104 cells/well (EpH4, 16 N)
onto Lab-Tek glass 8-chamber slides (NUNC, Rochester,
NY) for experiments. Chamber slides were coated with
150 μl of either Collagen type I (100 μg/ml, Sigma), fibro-
nectin (30 μg/ml, Sigma), Cell-Tak (1:100 dilution in PBS,
BD BioSciences, Bedford, MA), or Collagen I plus Cell-
Tak (1:100 dilution of Cell-Tak in Collagen I). Slides were
then incubated at 37°C for 30 min (Collagen type I and/
or Cell-Tak) or RT for 45 min (fibronectin) before wash-
ing with sterile water and drying under UV for 20 min.
Immunofluorescence
Cell monolayers were fixed with 2% paraformaldehyde
for 15 min at room temperature. Cells were then
permeabilized with 0.5% Triton X-100 for 5 minutes
before blocking with 2% BSA for one hour. Cells were
treated with rabbit anti-claudin-4 (1:200, Zymed, Carlsbad
CA), rat anti-ZO-1 (1:50, Santa Cruz Biotechnology), and/
or rabbit anti-Ki67 (1:100, Abcam, Cambridge, MA)
primary antibodies for 1 hour. After washing with
Phosphate Buffered Saline (PBS), cells were treated with
donkey anti-rabbit-CY3, donkey anti-rat-FITC (1:150,
Jackson ImmunoResearch Laboratories, West Grove, PA),
Alexa FluorW 647 Phalloidin (7.5 units/ml, Invitrogen,
Carlsbad, CA), and/or DAPI (5 μg/ml, MP Biochemicals,
Solon, OH) for 45 minutes. Monolayers were then washed
five times, five minutes each, with PBS and OPDA
(20 mg/ml, o-phenylenediamine dihydrochloride in 1 M
Tris, pH 8.5) was applied before addition of a coverslip.
Fluorescence was imaged on an Olympus Spinning Disk
confocal microscope, using SlideBook software (Intelligent
Imaging Innovations, Inc., Denver, CO, USA).
FITC-linked peptide
A FITC labeled DFYNP peptide (FITC-DFYNP-amide,
D-amino acid form) was synthesized in the Peptide and
Protein Chemistry Core, University of Colorado Anschutz
Medical Campus as described previously [28]. Cells were
treated with 400 μM FITC-DFYNP peptide for 1 hour
on ice before washing three times with ice-cold PBS
and immediately imaging. Fluorescence was imaged on
an Olympus Spinning Disk confocal microscope, using
SlideBook software (Intelligent Imaging Innovations,
Inc., Denver, CO, USA).
Scratch assay
Cells were grown on collagen I, Cell-Tak, or collagen plus
Cell-Tak until cells reached confluence (usually 5 days in
culture). A 200 μM pipette tip was used to scratch the
monolayers, creating a vertical cell-free gap. Media was
immediately changed to normal growth media or growth
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mutated peptide. Cells were incubated at 37°C for 4 hours
(EpH4, 16 N) or 24 hours (21PT, 21MT1, T47D, MCF7,
OVCAR3) before fixing with 2% paraformaldehyde for
15 min at room temperature. Cells were treated with
Alexa FluorW 647 Phalloidin and DAPI, washed with PBS,
coverslipped, and imaged as described above. Micrographs
of two fields of interest, near the center of the slide, were
taken and SlideBook software was used to measure the
thickness of the gap (20 measurements along the length
of each imaged scratch were taken for each well under
each condition).
shRNA knockdown
T47D breast tumor cells were plated at 3.2 × 104 in a
96-well plate and incubated at 37°C for 24 hours. When
cells were 70% confluent, 15 μl of claudin-4 shRNA
lentiviral suspension (University of Colorado Functional
Genomics Facility, Boulder, CO, USA) was added to each
well and cells were incubated overnight at 37°C. Medium
was then removed and replaced with fresh medium.
Twenty-four hours later the cells were treated with 2 μg/ml
puromycin to select for transduced cells. Colonies of cells
were selected and expanded for experiments. Western blot
analysis was performed to select cells with most significant
reduction in claudin-4 expression. Knockdown of claudin-4
expression was confirmed with immunofluorescence
analysis of the cultured cells as described above. This
experiment also confirms the specificity of the antibody.
Statistics
Data are presented as Mean ± Standard Error of the
Mean (s.e.m.). An unpaired Student t test was used for
statistical comparison between control and treatment
groups. A p value of < 0.05 was considered significant.
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